

Guido Grassi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8101607/publications.pdf>

Version: 2024-02-01

490
papers

41,041
citations

6254

80
h-index

2747

192
g-index

497
all docs

497
docs citations

497
times ranked

30327
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	2.2	6,826
2	2007 Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1105-1187.	0.5	4,778
3	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.	2.2	1,617
4	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009, 27, 2121-2158.	0.5	1,236
5	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007, 25, 1751-1762.	0.5	1,152
6	Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population. <i>Circulation</i> , 2005, 111, 1777-1783.	1.6	896
7	Hypertension. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18014.	30.5	636
8	Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure. <i>Hypertension</i> , 2006, 47, 846-853.	2.7	613
9	Advances in heart rate variability signal analysis: joint position statement by the e-Cardiology ESC Working Group and the European Heart Rhythm Association co-endorsed by the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1341-1353.	1.7	589
10	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. <i>European Heart Journal</i> , 2021, 42, 2439-2454.	2.2	491
11	Sympathetic Activation in Obese Normotensive Subjects. <i>Hypertension</i> , 1995, 25, 560-563.	2.7	472
12	Baroreflex Control of Sympathetic Nerve Activity in Essential and Secondary Hypertension. <i>Hypertension</i> , 1998, 31, 68-72.	2.7	443
13	The Sympathetic Nervous System Alterations in Human Hypertension. <i>Circulation Research</i> , 2015, 116, 976-990.	4.5	441
14	The Autonomic Nervous System and Hypertension. <i>Circulation Research</i> , 2014, 114, 1804-1814.	4.5	438
15	Obesity and hypertension. <i>Pharmacological Research</i> , 2017, 122, 1-7.	7.1	430
16	Sympathetic Activation in the Pathogenesis of Hypertension and Progression of Organ Damage. <i>Hypertension</i> , 1999, 34, 724-728.	2.7	428
17	How to assess sympathetic activity in humans. <i>Journal of Hypertension</i> , 1999, 17, 719-734.	0.5	383
18	Sympathetic Activation and Loss of Reflex Sympathetic Control in Mild Congestive Heart Failure. <i>Circulation</i> , 1995, 92, 3206-3211.	1.6	351

#	ARTICLE	IF	CITATIONS
19	Age and Multimorbidity Predict Death Among COVID-19 Patients. <i>Hypertension</i> , 2020, 76, 366-372.	2.7	330
20	Long-Term Prognostic Value of Blood Pressure Variability in the General Population. <i>Hypertension</i> , 2007, 49, 1265-1270.	2.7	329
21	Body Weight Reduction, Sympathetic Nerve Traffic, and Arterial Baroreflex in Obese Normotensive Humans. <i>Circulation</i> , 1998, 97, 2037-2042.	1.6	321
22	The sympathetic nervous system and the metabolic syndrome. <i>Journal of Hypertension</i> , 2007, 25, 909-920.	0.5	318
23	Assessment of Sympathetic Cardiovascular Drive in Human Hypertension. <i>Hypertension</i> , 2009, 54, 690-697.	2.7	316
24	2007 ESH&ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2007, 16, 135-232.	1.5	292
25	Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. <i>Journal of Hypertension</i> , 2004, 22, 2363-2369.	0.5	271
26	Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal Failure. <i>Hypertension</i> , 2011, 57, 846-851.	2.7	268
27	Blood Pressure Variability and Organ Damage in a General Population. <i>Hypertension</i> , 2002, 39, 710-714.	2.7	261
28	Adrenergic and Reflex Abnormalities in Obesity-Related Hypertension. <i>Hypertension</i> , 2000, 36, 538-542.	2.7	259
29	Long-Term Risk of Sustained Hypertension in White-Coat or Masked Hypertension. <i>Hypertension</i> , 2009, 54, 226-232.	2.7	258
30	When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. <i>Journal of Hypertension</i> , 2009, 27, 923-934.	0.5	243
31	New-onset diabetes and antihypertensive drugs. <i>Journal of Hypertension</i> , 2006, 24, 3-10.	0.5	242
32	Systolic and diastolic blood pressure control in antihypertensive drug trials. <i>Journal of Hypertension</i> , 2002, 20, 1461-1464.	0.5	233
33	Heart rate as marker of sympathetic activity. <i>Journal of Hypertension</i> , 1998, 16, 1635-1639.	0.5	231
34	Role of the sympathetic nervous system in human hypertension. <i>Journal of Hypertension</i> , 1998, 16, 1979-1987.	0.5	231
35	Dissociation Between Muscle and Skin Sympathetic Nerve Activity in Essential Hypertension, Obesity, and Congestive Heart Failure. <i>Hypertension</i> , 1998, 31, 64-67.	2.7	228
36	ESH Position Paper. <i>Journal of Hypertension</i> , 2012, 30, 837-841.	0.5	227

#	ARTICLE	IF	CITATIONS
37	Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study. Hypertension, 2007, 49, 40-47.	2.7	221
38	Sympathetic Neural Activity in Hypertension and Related Diseases. American Journal of Hypertension, 2010, 23, 1052-1060.	2.0	203
39	Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals. Journal of Hypertension, 2003, 21, 1761-1769.	0.5	202
40	Obstructive Sleep Apneaâ€œDependent and â€œIndependent Adrenergic Activation in Obesity. Hypertension, 2005, 46, 321-325.	2.7	196
41	Adrenergic, Metabolic, and Reflex Abnormalities in Reverse and Extreme Dipper Hypertensives. Hypertension, 2008, 52, 925-931.	2.7	178
42	Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet, The, 2019, 394, 2173-2183.	13.7	177
43	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension, 2020, 75, 302-308.	2.7	177
44	Seasonal variations in home and ambulatory blood pressure in the PAMELA population. Journal of Hypertension, 1998, 16, 1585-1592.	0.5	175
45	Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. Journal of Hypertension, 2006, 24, 603-610.	0.5	175
46	Sympathetic regulation of vascular function in health and disease. Frontiers in Physiology, 2012, 3, 284.	2.8	174
47	Effects of Chronic ACE Inhibition on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure. Circulation, 1997, 96, 1173-1179.	1.6	173
48	Sympathetic and Baroreflex Cardiovascular Control in Hypertension-Related Left Ventricular Dysfunction. Hypertension, 2009, 53, 205-209.	2.7	157
49	Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proofâ€œofâ€œconcept study. European Journal of Heart Failure, 2014, 16, 977-983.	7.1	152
50	Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. Journal of Hypertension, 2009, 27, 2458-2464.	0.5	144
51	Long-Term Prognostic Value of White Coat Hypertension. Hypertension, 2013, 62, 168-174.	2.7	143
52	Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications. European Journal of Clinical Investigation, 2015, 45, 1367-1375.	3.4	140
53	Evidence for a critical role of the sympathetic nervous system in hypertension. Journal of the American Society of Hypertension, 2016, 10, 457-466.	2.3	138
54	The â€œneuroadrenergic hypothesisâ€™ in hypertension: current evidence. Experimental Physiology, 2010, 95, 581-586.	2.0	135

#	ARTICLE	IF	CITATIONS
55	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2012, 30, 1047-1055.	0.5	134
56	Ambulatory and Home Blood Pressure Normality in the Elderly. <i>Hypertension</i> , 1997, 30, 1-6.	2.7	131
57	Short- and Long-Term Neuroadrenergic Effects of Moderate Dietary Sodium Restriction in Essential Hypertension. <i>Circulation</i> , 2002, 106, 1957-1961.	1.6	126
58	International Expert Consensus Statement. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2031-2045.	2.8	124
59	Neurogenic Abnormalities in Masked Hypertension. <i>Hypertension</i> , 2007, 50, 537-542.	2.7	121
60	Sympathetic Overdrive and Cardiovascular Risk in the Metabolic Syndrome. <i>Hypertension Research</i> , 2006, 29, 839-847.	2.7	118
61	Excessive Sympathetic Activation in Heart Failure With Obesity and Metabolic Syndrome. <i>Hypertension</i> , 2007, 49, 535-541.	2.7	117
62	Management of the hypertensive patient with elevated heart rate. <i>Journal of Hypertension</i> , 2016, 34, 813-821.	0.5	116
63	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017, 19, 1361-1378.	7.1	115
64	Comparison between Reproducibility and Sensitivity of Muscle Sympathetic Nerve Traffic and Plasma Noradrenaline in Man. <i>Clinical Science</i> , 1997, 92, 285-289.	4.3	114
65	Prevalence of Left Ventricular Hypertrophy in Hypertensive Patients Without and With Blood Pressure Control. <i>Hypertension</i> , 2002, 39, 744-749.	2.7	104
66	Sympathetic nervous system. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 46-51.	2.0	102
67	Aggressive Blood Pressure Lowering Is Dangerous: The J-Curve. <i>Hypertension</i> , 2014, 63, 29-36.	2.7	101
68	Relationship of Office, Home, and Ambulatory Blood Pressure to Blood Glucose and Lipid Variables in the PAMELA Population. <i>Hypertension</i> , 2005, 45, 1072-1077.	2.7	99
69	Structural and Functional Alterations of Subcutaneous Small Resistance Arteries in Severe Human Obesity. <i>Obesity</i> , 2010, 18, 92-98.	3.0	98
70	Systolic vs Diastolic Blood Pressure Control in the Hypertensive Patients of the PAMELA Population. <i>Archives of Internal Medicine</i> , 2002, 162, 582.	3.8	97
71	Effects of Hypertension and Obesity on the Sympathetic Activation of Heart Failure Patients. <i>Hypertension</i> , 2003, 42, 873-877.	2.7	95
72	Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. <i>Journal of Hypertension</i> , 2009, 27, 1672-1678.	0.5	95

#	ARTICLE	IF	CITATIONS
73	Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. <i>International Journal of Cardiology</i> , 2014, 177, 1020-1025.	1.7	93
74	Muscle and Skin Sympathetic Nerve Traffic During the "White-Coat" Effect. <i>Circulation</i> , 1999, 100, 222-225.	1.6	91
75	Mechanisms and Clinical Implications of Blood Pressure Variability. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, S15-S19.	1.9	90
76	Diurnal blood pressure variation and sympathetic activity. <i>Hypertension Research</i> , 2010, 33, 381-385.	2.7	89
77	Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: An updated review. <i>Journal of Clinical Hypertension</i> , 2017, 19, 713-721.	2.0	88
78	Sympathetic Neural Overdrive in the Obese and Overweight State. <i>Hypertension</i> , 2019, 74, 349-358.	2.7	87
79	Sympathetic Modulation of Radial Artery Compliance in Congestive Heart Failure. <i>Hypertension</i> , 1995, 26, 348-354.	2.7	86
80	Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. <i>Journal of Hypertension</i> , 2000, 18, 587-593.	0.5	83
81	Impairment of Thermoregulatory Control of Skin Sympathetic Nerve Traffic in the Elderly. <i>Circulation</i> , 2003, 108, 729-735.	1.6	80
82	Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates. <i>Hypertension</i> , 2018, 72, 483-491.	2.7	79
83	Counteracting the sympathetic nervous system in essential hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 513-519.	2.0	77
84	Diagnosis and management of patients with white-coat and masked hypertension. <i>Nature Reviews Cardiology</i> , 2011, 8, 686-693.	13.7	75
85	Total Cardiovascular Risk, Blood Pressure Variability and Adrenergic Overdrive in Hypertension: Evidence, Mechanisms and Clinical Implications. <i>Current Hypertension Reports</i> , 2012, 14, 333-338.	3.5	74
86	Renal Denervation Update From the "International Sympathetic Nervous System Summit. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3006-3017.	2.8	74
87	Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 175-179.	2.2	73
88	Treatment of hypertension: The ESH/ESC guidelines recommendations. <i>Pharmacological Research</i> , 2018, 128, 315-321.	7.1	73
89	Two-Drug Combinations as First-Step Antihypertensive Treatment. <i>Circulation Research</i> , 2019, 124, 1113-1123.	4.5	73
90	COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?. <i>Pharmacological Research</i> , 2020, 158, 104906.	7.1	72

#	ARTICLE	IF	CITATIONS
91	Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan. <i>Blood Pressure</i> , 2015, 24, 55-60.	1.5	71
92	Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. <i>Journal of Hypertension</i> , 1998, 16, 1789-1796.	0.5	70
93	Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. <i>European Heart Journal</i> , 2011, 32, 218-225.	2.2	70
94	White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage. <i>Journal of Hypertension</i> , 2015, 33, 24-32.	0.5	70
95	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. <i>Journal of Hypertension</i> , 2020, 38, 412-419.	0.5	70
96	Heart Rate, Sympathetic Cardiovascular Influences, and The Metabolic Syndrome. <i>Progress in Cardiovascular Diseases</i> , 2009, 52, 31-37.	3.1	69
97	Untreated Masked Hypertension and Subclinical Cardiac Damage: A Systematic Review and Meta-analysis. <i>American Journal of Hypertension</i> , 2015, 28, 806-813.	2.0	69
98	New developments in the pathogenesis of obesity-induced hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1499-1508.	0.5	68
99	Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. <i>Journal of Hypertension</i> , 2001, 19, 1713-1716.	0.5	67
100	Relationship Among Morning Blood Pressure Surge, 24-Hour Blood Pressure Variability, and Cardiovascular Outcomes in a White Population. <i>Hypertension</i> , 2014, 64, 943-950.	2.7	66
101	Blood Pressure Responses to Renal Denervation Precede and Are Independent of the Sympathetic and Baroreflex Effects. <i>Hypertension</i> , 2015, 65, 1209-1216.	2.7	65
102	COVID-19 and arterial hypertension: Hypothesis or evidence?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1120-1126.	2.0	65
103	Heart rate as a predictor of cardiovascular risk. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12892.	3.4	64
104	Long-Term Sympathoinhibitory Effects of Surgically Induced Weight Loss in Severe Obese Patients. <i>Hypertension</i> , 2014, 64, 431-437.	2.7	62
105	Coronavirus disease 2019 and cardiovascular complications: focused clinical review. <i>Journal of Hypertension</i> , 2021, 39, 1282-1292.	0.5	62
106	Sympathetic nerve traffic and baroreflex function in optimal, normal, and high-normal blood pressure states. <i>Journal of Hypertension</i> , 2015, 33, 1411-1417.	0.5	61
107	Isolated systolic hypertension in the young. <i>Journal of Hypertension</i> , 2018, 36, 1222-1236.	0.5	61
108	Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population. <i>Journal of Hypertension</i> , 2018, 36, 1492-1498.	0.5	61

#	ARTICLE	IF	CITATIONS
109	Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events. <i>Journal of Hypertension</i> , 2010, 28, 999-1006.	0.5	60
110	Prevalence of electrocardiographic left ventricular hypertrophy in human hypertension. <i>Journal of Hypertension</i> , 2012, 30, 2066-2073.	0.5	60
111	Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe. <i>Journal of Hypertension</i> , 2013, 31, 2018-2024.	0.5	58
112	Prognostic value of serum uric acid. <i>Journal of Hypertension</i> , 2014, 32, 1237-1244.	0.5	57
113	Angiotensinâ€“sympathetic system interactions in cardiovascular and metabolic disease. <i>Journal of Hypertension</i> , 2006, 24, S51-S56.	0.5	56
114	Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. <i>Journal of Hypertension</i> , 2008, 26, 1602-1611.	0.5	56
115	Prognostic Significance of Left Atrial Enlargement in a General Population. <i>Hypertension</i> , 2014, 64, 1205-1211.	2.7	56
116	Blood Pressure Non-Dipping and Obstructive Sleep Apnea Syndrome: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1367.	2.4	55
117	Short-Versus Long-Term Effects of Different Dihydropyridines on Sympathetic and Baroreflex Function in Hypertension. <i>Hypertension</i> , 2003, 41, 558-562.	2.7	54
118	Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system?. <i>Journal of Hypertension</i> , 2009, 27, 1341-1349.	0.5	53
119	Normal values of left-ventricular mass. <i>Journal of Hypertension</i> , 2012, 30, 997-1003.	0.5	53
120	Evaluation of microvascular structure in humans. <i>Journal of Hypertension</i> , 2014, 32, 2120-2129.	0.5	53
121	Aortic root diameter and risk of cardiovascular events in a general population. <i>Journal of Hypertension</i> , 2014, 32, 1879-1887.	0.5	53
122	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. <i>PLoS ONE</i> , 2020, 15, e0237297.	2.5	51
123	Baroreflex Impairment by Low Sodium Diet in Mild or Moderate Essential Hypertension. <i>Hypertension</i> , 1997, 29, 802-807.	2.7	51
124	Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. <i>Journal of Hypertension</i> , 2004, 22, 2387-2396.	0.5	50
125	Leptin, sympathetic nervous system, and baroreflex function. <i>Current Hypertension Reports</i> , 2004, 6, 236-240.	3.5	49
126	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021, 39, 62-69.	0.5	49

#	ARTICLE	IF	CITATIONS
127	High Normal Blood Pressure and Left Ventricular Hypertrophy Echocardiographic Findings From the PAMELA Population. <i>Hypertension</i> , 2019, 73, 612-619.	2.7	48
128	Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. <i>Journal of Hypertension</i> , 2019, 37, 443-448.	0.5	47
129	Baroreflex Function in Hypertension: Consequences for Antihypertensive Therapy. <i>Progress in Cardiovascular Diseases</i> , 2006, 48, 407-415.	3.1	46
130	Sympathetic Nerve Traffic and Asymmetric Dimethylarginine in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2620-2627.	4.5	46
131	Adverse Prognostic Value of Persistent Office Blood Pressure Elevation in White Coat Hypertension. <i>Hypertension</i> , 2015, 66, 437-444.	2.7	46
132	Sympathomodulatory Effects of Antihypertensive Drug Treatment. <i>American Journal of Hypertension</i> , 2016, 29, 665-675.	2.0	46
133	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021, 39, 333-340.	0.5	46
134	Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. <i>Clinical Science</i> , 2001, 101, 141-146.	4.3	45
135	Sympathetic Nervous System, Sleep, and Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 74.	3.5	45
136	Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries. <i>Journal of Hypertension</i> , 2019, 37, 380-388.	0.5	45
137	Efficacy and tolerability profile of nebivolol vs atenolol in mild to moderate essential hypertension: Results of a double-blind randomized multicentre trial. <i>Blood Pressure</i> , 2003, 12, 35-40.	1.5	44
138	Sympathetic and Baroreflex Function in Hypertension: Implications for Current and New Drugs. <i>Current Pharmaceutical Design</i> , 2004, 10, 3579-3589.	1.9	44
139	Sustained Sympathoinhibitory Effects of Cardiac Resynchronization Therapy in Severe Heart Failure. <i>Hypertension</i> , 2004, 44, 727-731.	2.7	44
140	Essential hypertension and the sympathetic nervous system. <i>Neurological Sciences</i> , 2008, 29, 33-36.	1.9	44
141	Sympathetic Mechanisms, Organ Damage, and Antihypertensive Treatment. <i>Current Hypertension Reports</i> , 2011, 13, 303-308.	3.5	44
142	Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. <i>Journal of Hypertension</i> , 2021, 39, 1077-1089.	0.5	44
143	Nutraceuticals and blood pressure control: a European Society of Hypertension position document. <i>Journal of Hypertension</i> , 2020, 38, 799-812.	0.5	43
144	Long-term chronic baroreflex activation. <i>Journal of Hypertension</i> , 2015, 33, 1704-1708.	0.5	42

#	ARTICLE	IF	CITATIONS
145	Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 365-371.	1.6	42
146	Is white-coat hypertension a risk factor for carotid atherosclerosis? A review and meta-analysis. <i>Blood Pressure Monitoring</i> , 2015, 20, 57-63.	0.8	41
147	Blood pressure control in hypertension. Pros and cons of available treatment strategies. <i>Journal of Hypertension</i> , 2017, 35, 225-233.	0.5	41
148	Reinforcement of the adrenergic overdrive in the metabolic syndrome complicated by obstructive sleep apnea. <i>Journal of Hypertension</i> , 2010, 28, 1313-1320.	0.5	41
149	Defining ambulatory and home blood pressure normality: further considerations based on data from the PAMELA study. <i>Journal of Hypertension</i> , 2001, 19, 995-999.	0.5	40
150	Role of the Sympathetic Nervous System in Hypertension and Hypertension-Related Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 89-105.	2.2	40
151	Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. <i>Journal of Hypertension</i> , 2015, 33, 2519-2525.	0.5	40
152	Sympathetic activation in congestive heart failure: Reproducibility of neuroadrenergic markers. <i>European Journal of Heart Failure</i> , 2008, 10, 1186-1191.	7.1	39
153	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. <i>Journal of Hypertension</i> , 2014, 32, 1741-1750.	0.5	39
154	Sympathetic Nerve Traffic Responses to Surgical Removal of Pheochromocytoma. <i>Hypertension</i> , 1999, 34, 461-465.	2.7	38
155	Limited reproducibility of MUCH and WUCH: evidence from the ELSA study. <i>European Heart Journal</i> , 2020, 41, 1565-1571.	2.2	38
156	Hypertension and COVID-19: Ongoing Controversies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 639222.	2.4	38
157	Radial Artery Compliance in Young, Obese, Normotensive Subjects. <i>Hypertension</i> , 1995, 26, 984-988.	2.7	38
158	Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias. <i>Acta Physiologica Scandinavica</i> , 2003, 177, 399-404.	2.2	37
159	European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. <i>Journal of Hypertension</i> , 2009, 27, 207-211.	0.5	37
160	Cardiovascular Risk Associated With White-Coat Hypertension. <i>Hypertension</i> , 2017, 70, 668-675.	2.7	37
161	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 105-108.	2.2	37
162	Cardiopulmonary receptor regulation of renin release. <i>American Journal of Medicine</i> , 1988, 84, 97-104.	1.5	36

#	ARTICLE	IF	CITATIONS
163	Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications. <i>Current Vascular Pharmacology</i> , 2009, 7, 137-145.	1.7	36
164	Sex-related relationships between uric acid and target organ damage in hypertension. <i>Journal of Clinical Hypertension</i> , 2018, 20, 193-200.	2.0	36
165	Effects of Celiprolol on Reflex Control of the Cardiovascular System in Essential Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1986, 8, S67-S74.	1.9	35
166	Patterns of regional sympathetic nerve traffic in preascitic and ascitic cirrhosis. <i>Hepatology</i> , 2001, 34, 1113-1118.	7.3	35
167	Determinants of carotid-femoral pulse wave velocity progression in hypertensive patients over a 3.7 years follow-up. <i>Blood Pressure</i> , 2018, 27, 32-40.	1.5	35
168	Risk of mortality in relation to an updated classification of left ventricular geometric abnormalities in a general population. <i>Journal of Hypertension</i> , 2015, 33, 2133-2140.	0.5	34
169	Sympathetic neural overdrive in congestive heart failure and its correlates. <i>Journal of Hypertension</i> , 2019, 37, 1746-1756.	0.5	34
170	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. <i>Journal of Nephrology</i> , 2022, 35, 211-221.	2.0	34
171	Association Between the European Society of Cardiology/European Society of Hypertension Heart Rate Thresholds for Cardiovascular Risk and Neuroadrenergic Markers. <i>Hypertension</i> , 2020, 76, 577-582.	2.7	33
172	White-Coat Hypertension: Pathophysiological and Clinical Aspects: Excellence Award for Hypertension Research 2020. <i>Hypertension</i> , 2021, 78, 1677-1688.	2.7	33
173	The effects of sex and method of blood pressure measurement on genetic associations with blood pressure in the PAMELA study. <i>Journal of Hypertension</i> , 2010, 28, 465-477.	0.5	32
174	Effects of Chronic Clonidine Administration on Sympathetic Nerve Traffic and Baroreflex Function in Heart Failure. <i>Hypertension</i> , 2001, 38, 286-291.	2.7	31
175	Left atrial function in elite athletes: A meta-analysis of two-dimensional speckle tracking echocardiographic studies. <i>Clinical Cardiology</i> , 2019, 42, 579-587.	1.8	31
176	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. <i>Clinical Research in Cardiology</i> , 2021, 110, 1073-1082.	3.3	31
177	Impact of the metabolic syndrome on subcutaneous microcirculation in obese patients. <i>Journal of Hypertension</i> , 2010, 28, 1708-1714.	0.5	30
178	Sympathetic activation in congestive heart failure: an updated overview. <i>Heart Failure Reviews</i> , 2021, 26, 173-182.	3.9	30
179	Sympathetic Response to Ventricular Extrasystolic Beats in Hypertension and Heart Failure. <i>Hypertension</i> , 2002, 39, 886-891.	2.7	28
180	Neurogenic Hypertension: Is the Enigma of Its Origin Near the Solution?. <i>Hypertension</i> , 2004, 43, 154-155.	2.7	28

#	ARTICLE	IF	CITATIONS
181	Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias. <i>Journal of Hypertension</i> , 2004, 22, 1747-1753.	0.5	28
182	Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy. <i>Journal of Hypertension</i> , 2017, 35, 2532-2536.	0.5	28
183	Neurohumoral and Endothelial Responses to Heated Water-Based Exercise in Resistant Hypertensive Patients. <i>Circulation Journal</i> , 2017, 81, 339-345.	1.6	28
184	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
185	White Coat Hypertension: to Treat or Not to Treat?. <i>Current Hypertension Reports</i> , 2016, 18, 80.	3.5	27
186	The Heterogeneous Nature of White-Coat Hypertension —. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2044-2046.	2.8	27
187	Night-time heart rate nondipping. <i>Journal of Hypertension</i> , 2018, 36, 1311-1317.	0.5	27
188	Muscle and skin sympathetic nerve traffic during physician and nurse blood pressure measurement. <i>Journal of Hypertension</i> , 2013, 31, 1131-1135.	0.5	26
189	Sympathetic activation secondary to chronic kidney disease. <i>Journal of Hypertension</i> , 2014, 32, 1751-1761.	0.5	26
190	The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?. <i>Heart Failure Reviews</i> , 2018, 23, 631-639.	3.9	26
191	Differing associations for sport versus occupational physical activity and cardiovascular risk. <i>Heart</i> , 2018, 104, 1165-1172.	2.9	26
192	Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2020, 38, 1436-1442.	0.5	26
193	Sympathetic activation in cardiovascular and renal disease. <i>Journal of Nephrology</i> , 2009, 22, 190-5.	2.0	26
194	Editorial. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 5-12.	2.1	25
195	The Sympathetic Nervous System and New Nonpharmacologic Approaches to Treating Hypertension: A Focus on Renal Denervation. <i>Canadian Journal of Cardiology</i> , 2012, 28, 311-317.	1.7	25
196	Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2021, 39, 408-416.	0.5	25
197	Sympathomoderating influence of benazepril in essential hypertension. <i>Journal of Hypertension</i> , 1992, 10, 373-378.	0.5	24
198	Behaviour of regional adrenergic outflow in mild-to-moderate renal failure. <i>Journal of Hypertension</i> , 2009, 27, 562-566.	0.5	24

#	ARTICLE	IF	CITATIONS
199	Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population. <i>American Journal of Hypertension</i> , 2017, 30, 279-285.	2.0	24
200	Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options. <i>Heart Failure Reviews</i> , 2020, 25, 295-303.	3.9	24
201	Myocardial strain in hypertension: a meta-analysis of two-dimensional speckle tracking echocardiographic studies. <i>Journal of Hypertension</i> , 2021, 39, 2103-2112.	0.5	24
202	Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 178-185.	2.6	24
203	Lercanidipine in the management of hypertension: An update. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2017, 8, 155.	0.4	24
204	Influence of sleep disturbances on age at onset and long-term incidence of major cardiovascular events: the MONICA-Brianza and PAMELA cohort studies. <i>Sleep Medicine</i> , 2016, 21, 126-132.	1.6	23
205	Effects of the Combination of Low-Dose Nifedipine GITS 20 mg and Losartan 50 mg in Patients with Mild to Moderate Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 300-305.	1.9	22
206	Role of Ambulatory Blood Pressure Monitoring in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 232-237.	3.5	22
207	Regional differences in sympathetic activation in lean and obese normotensive individuals with obstructive sleep apnoea. <i>Journal of Hypertension</i> , 2014, 32, 383-388.	0.5	22
208	Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 838-846.	3.3	22
209	Age- and Sex-Specific Reference Values for Media/Lumen Ratio in Small Arteries and Relationship With Risk Factors. <i>Hypertension</i> , 2018, 71, 1193-1200.	2.7	22
210	Right heart remodeling induced by arterial hypertension: Could strain assessment be helpful?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 400-407.	2.0	22
211	Association between uric acid and pulse wave velocity in hypertensive patients and in the general population: a systematic review and meta-analysis. <i>Blood Pressure</i> , 2020, 29, 220-231.	1.5	22
212	Elevated heart rate and cardiovascular risk in hypertension. <i>Journal of Hypertension</i> , 2021, 39, 1060-1069.	0.5	22
213	Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: Rationale and options. <i>Current Hypertension Reports</i> , 2003, 5, 277-280.	3.5	21
214	Sympathetic Activation in Obesity. <i>Hypertension</i> , 2010, 56, 338-340.	2.7	21
215	Risk of new-onset metabolic syndrome associated with white-coat and masked hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1833-1839.	0.5	21
216	Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis. <i>Journal of Hypertension</i> , 2020, 38, 936-942.	0.5	21

#	ARTICLE	IF	CITATIONS
217	Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 5-11.	2.2	21
218	Adding Home and/or Ambulatory Blood Pressure to Office Blood Pressure for Cardiovascular Risk Prediction. Hypertension, 2021, 77, 640-649.	2.7	21
219	Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy. Journal of Hypertension, 2015, 33, 346-353.	0.5	20
220	Pre-hypertension and subclinical cardiac damage: A meta-analysis of echocardiographic studies. International Journal of Cardiology, 2018, 270, 302-308.	1.7	20
221	The importance of endothelial dysfunction in resistance artery remodelling and cardiovascular risk. Cardiovascular Research, 2019, 116, 429-437.	3.8	20
222	Sympathetic overdrive in the metabolic syndrome: meta-analysis of published studies. Journal of Hypertension, 2020, 38, 565-572.	0.5	20
223	Central and peripheral sympathetic activation in heart failure. Cardiovascular Research, 2022, 118, 1857-1871.	3.8	20
224	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. Journal of Human Hypertension, 2022, 36, 976-982.	2.2	20
225	Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension. Journal of Hypertension, 2021, 39, 376-380.	0.5	20
226	Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension, 2022, 79, 1153-1166.	2.7	20
227	Effects of Amlodipine on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure. Hypertension, 1999, 33, 671-675.	2.7	19
228	Reproducibility patterns of plasma norepinephrine and muscle sympathetic nerve traffic in human obesity. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 469-475.	2.6	19
229	Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome. Metabolism: Clinical and Experimental, 2009, 58, 1446-1451.	3.4	19
230	Metabolic syndrome and subclinical carotid damage. Journal of Hypertension, 2018, 36, 23-30.	0.5	19
231	Incident Left Ventricular Hypertrophy in Masked Hypertension. Hypertension, 2019, 74, 56-62.	2.7	19
232	<p>Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?</p>. Integrated Blood Pressure Control, 2020, Volume 13, 63-69.	1.2	19
233	Structural Alterations of the Retinal Microcirculation in the "Prehypertensive" High-Normal Blood Pressure State. Current Pharmaceutical Design, 2013, 19, 2375-2381.	1.9	19
234	The "Curve" Problem Revisited: Old and New Findings. Current Hypertension Reports, 2010, 12, 290-295.	3.5	18

#	ARTICLE	IF	CITATIONS
235	Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population. <i>Journal of Hypertension</i> , 2011, 29, 1121-1127.	0.5	18
236	New-onset left atrial enlargement in a general population. <i>Journal of Hypertension</i> , 2016, 34, 1838-1845.	0.5	18
237	Job strain and the incidence of coronary heart diseases: does the association differ among occupational classes? A contribution from a pooled analysis of Northern Italian cohorts. <i>BMJ Open</i> , 2017, 7, e014119.	1.9	18
238	Extreme dipping. <i>Journal of Hypertension</i> , 2019, 37, 1917-1926.	0.5	18
239	Targeting subclinical organ damage in obstructive sleep apnea: a narrative review. <i>Journal of Human Hypertension</i> , 2021, 35, 26-36.	2.2	18
240	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 713652.	2.4	18
241	The association between 24-h blood pressure patterns and left ventricular mechanics. <i>Journal of Hypertension</i> , 2020, 38, 282-288.	0.5	18
242	Sympathetic nervous system and hypertension: New evidences. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2022, 238, 102954.	2.8	18
243	Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. <i>Blood Pressure Supplement</i> , 2003, 2, 35-40.	0.2	18
244	White-Coat Hypertension Without Organ Damage: Impact on Long-Term Mortality, New Hypertension, and New Organ Damage. <i>Hypertension</i> , 2022, 79, 1057-1066.	2.7	18
245	Baroreceptor Control of the Circulation in Man. An Update. <i>Clinical and Experimental Hypertension</i> , 1995, 17, 387-397.	1.3	17
246	Impaired baroreflex sensitivity as a potential marker of cardiovascular risk in hypertension. <i>Journal of Hypertension</i> , 2008, 26, 1303-1304.	0.5	17
247	Management of essential hypertension. <i>British Medical Bulletin</i> , 2010, 94, 189-199.	6.9	17
248	Renal denervation in cardiometabolic disease: Concepts, achievements and perspectives. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 77-83.	2.6	17
249	Clinical and prognostic value of hypertensive cardiac damage in the PAMELA Study. <i>Hypertension Research</i> , 2017, 40, 329-335.	2.7	17
250	Antihypertensive treatment and renal protection: Is there a JÉcurve relationship?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1560-1574.	2.0	17
251	Obstructive sleep apnoea syndrome and left ventricular hypertrophy: a meta-analysis of echocardiographic studies. <i>Journal of Hypertension</i> , 2020, 38, 1640-1649.	0.5	17
252	Hypertension and Periodontitis: A Joint Report by the Italian Society of Hypertension (SIIA) and the Italian Society of Periodontology and Implantology (SIdP). <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 427-438.	2.2	17

#	ARTICLE	IF	CITATIONS
253	Sympathetic nerve traffic and blood pressure changes after bilateral renal denervation in resistant hypertension: a time-integrated analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1351-1356.	0.7	16
254	Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. <i>Journal of Hypertension</i> , 2017, 35, 1685-1690.	0.5	16
255	Association of metabolic syndrome with carotid thickening and plaque in the general population: A meta-analysis. <i>Journal of Clinical Hypertension</i> , 2018, 20, 4-10.	2.0	16
256	Pulse wave velocity progression over a medium-term follow-up in hypertensives: Focus on uric acid. <i>Journal of Clinical Hypertension</i> , 2019, 21, 975-983.	2.0	16
257	Sympathetic Overactivation in Patients With Essential Hypertension and Hepatic Iron Overload. <i>Hypertension</i> , 2020, 76, 1444-1450.	2.7	16
258	Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation. <i>Current Hypertension Reports</i> , 2021, 23, 10.	3.5	16
259	The Sympathetic Nervous System in Hypertension: Roadmap Update of a Long Journey. <i>American Journal of Hypertension</i> , 2021, 34, 1247-1254.	2.0	16
260	Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. <i>Clinical Science</i> , 2001, 101, 141.	4.3	15
261	Metabolic syndrome and cardiometabolic risk: An update. <i>Blood Pressure</i> , 2009, 18, 7-16.	1.5	15
262	Hypertensive heart disease beyond left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2018, 36, 744-753.	0.5	15
263	Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases: A Consensus Document by the Italian Society of Hypertension (SIIA). <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 85-102.	2.2	15
264	Sleep Apnea and Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 23-31.	2.2	15
265	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1245-1252.	2.6	15
266	Angiotensin II as the link between nitric oxide and neuroadrenergic function. <i>Journal of Hypertension</i> , 2005, 23, 935-937.	0.5	14
267	Heart rate as a sympathetic marker during acute adrenergic challenge. <i>Journal of Hypertension</i> , 2008, 26, 70-75.	0.5	14
268	Within-visit BP variability, cardiovascular risk factors, and BP control in central and eastern Europe. <i>Journal of Hypertension</i> , 2015, 33, 2250-2256.	0.5	14
269	Specific Blood Pressure Targets for Patients With Diabetic Nephropathy?. <i>Diabetes Care</i> , 2016, 39, S228-S233.	8.6	14
270	Does <sc>QRS</sc> Voltage Correction by Body Mass Index Improve the Accuracy of Electrocardiography in Detecting Left Ventricular Hypertrophy and Predicting Cardiovascular Events in a General Population?. <i>Journal of Clinical Hypertension</i> , 2016, 18, 415-421.	2.0	14

#	ARTICLE	IF	CITATIONS
271	Baroreflex activation therapy systems: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2019, 16, 1025-1033.	2.8	14
272	Pre-hypertension and subclinical carotid damage: a meta-analysis. <i>Journal of Human Hypertension</i> , 2019, 33, 34-40.	2.2	14
273	Systolic blood pressure: an underestimated cardiovascular risk factor. <i>Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension</i> , 2002, 20, S21-7.	0.1	14
274	Evaluating sympathetic activity in human hypertension. <i>Journal of Hypertension</i> , 1993, 11, S13??S19.	0.5	13
275	Obesity and vascular stiffness: when body fat has an adverse impact on arterial dynamics. <i>Journal of Hypertension</i> , 2005, 23, 1789-1791.	0.5	13
276	Review: Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2008, 9, 66-74.	1.7	13
277	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1678-1688.	0.5	13
278	Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 393-400.	2.2	13
279	Sympathetic Nerve Traffic and Arterial Baroreflex Function in Apparent Drug-Resistant Hypertension. <i>Hypertension</i> , 2019, 74, 903-909.	2.7	13
280	When Office Blood Pressure Is Not Enough: The Case of Masked Hypertension. <i>American Journal of Hypertension</i> , 2019, 32, 225-233.	2.0	13
281	Targeting Concentric Left Ventricular Hypertrophy in Obstructive Sleep Apnea Syndrome. A Meta-analysis of Echocardiographic Studies. <i>American Journal of Hypertension</i> , 2020, 33, 310-315.	2.0	13
282	Sympathetic Neural Mechanisms Underlying Attended and Unattended Blood Pressure Measurement. <i>Hypertension</i> , 2021, 78, 1126-1133.	2.7	13
283	Post-prandial anorexigenic gut peptide, appetite and glucometabolic responses at different eating rates in obese patients undergoing laparoscopic sleeve gastrectomy. <i>Endocrine</i> , 2017, 55, 113-123.	2.3	12
284	The Prognostic Effect of Circadian Blood Pressure Pattern on Long-Term Cardiovascular Outcome Is Independent of Left Ventricular Remodeling. <i>Journal of Clinical Medicine</i> , 2019, 8, 2126.	2.4	12
285	The Complex Relationship Between Serum Uric Acid, Endothelial Function and Small Vessel Remodeling in Humans. <i>Journal of Clinical Medicine</i> , 2020, 9, 2027.	2.4	12
286	Obstructive Sleep Apnea, CPAP and Arterial Hypertension: A Cardiologist's View Point. <i>Archivos De Bronconeumologia</i> , 2022, 58, 461-462.	0.8	12
287	Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials. <i>Current Hypertension Reports</i> , 2007, 9, 299-304.	3.5	11
288	European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes. <i>Journal of Hypertension</i> , 2011, 29, 189-193.	0.5	11

#	ARTICLE	IF	CITATIONS
289	Cardiovascular consequences of poor compliance to antihypertensive therapy. <i>Blood Pressure</i> , 2011, 20, 196-203.	1.5	11
290	Hypertension-related target organ damage. <i>Journal of Hypertension</i> , 2013, 31, 1083-1085.	0.5	11
291	Neuroadrenergic disarray in pseudo-resistant and resistant hypertension. <i>Hypertension Research</i> , 2014, 37, 479-483.	2.7	11
292	Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1560-1567.	4.5	11
293	Metoprolol in the treatment of cardiovascular disease: a critical reappraisal. <i>Current Medical Research and Opinion</i> , 2018, 34, 1635-1643.	1.9	11
294	White-Coat Hypertension: the Neglected Subgroup in Hypertension. <i>Korean Circulation Journal</i> , 2018, 48, 552.	1.9	11
295	High-normal blood pressure and abnormal left ventricular geometric patterns. <i>Journal of Hypertension</i> , 2019, 37, 1312-1319.	0.5	11
296	Heart rate as cardiovascular risk factor. <i>Postgraduate Medicine</i> , 2020, 132, 358-367.	2.0	11
297	Heart rate as a predictor of cardiovascular risk. <i>Minerva Medica</i> , 2021, 112, 130-143.	0.9	11
298	Short- and Long-Term Reproducibility of Nighttime Blood Pressure Phenotypes and Nocturnal Blood Pressure Reduction. <i>Hypertension</i> , 2021, 77, 1745-1755.	2.7	11
299	New therapeutic approaches for resistant hypertension. <i>Journal of Nephrology</i> , 2012, 25, 276-281.	2.0	11
300	Mechanisms of sympathetic overactivity in patients with chronic renal failure: a role for chemoreflex activation?. <i>Journal of Hypertension</i> , 2007, 25, 47-49.	0.5	10
301	Novel Antihypertensive Therapies: Renal Sympathetic Nerve Ablation and Carotid Baroreceptor Stimulation. <i>Current Hypertension Reports</i> , 2012, 14, 567-572.	3.5	10
302	Alterations in sympathetic nerve traffic in genetic haemochromatosis before and after iron depletion therapy: a microneurographic study. <i>European Heart Journal</i> , 2016, 37, 988-995.	2.2	10
303	Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines. <i>Current Hypertension Reports</i> , 2019, 21, 67.	3.5	10
304	Exploring the interplay between job strain and different domains of physical activity on the incidence of coronary heart disease in adult men. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1877-1885.	1.8	10
305	Relationships between residual blood pressure variability and cognitive function in the general population of the PAMELA study. <i>Journal of Clinical Hypertension</i> , 2019, 21, 39-45.	2.0	10
306	Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 633878.	2.4	10

#	ARTICLE	IF	CITATIONS
307	Differential effects of enalaprilâ€“felodipine versus enalaprilâ€“lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. Journal of the American Society of Hypertension, 2016, 10, 244-251.	2.3	9
308	Endothelin contributes to the blood pressure rise triggered by hypoxia in severe obstructive sleep apnea. Journal of Hypertension, 2017, 35, 118-124.	0.5	9
309	The importance of pulse pressure on cardiovascular risk and total mortality in the general population: Is sex relevant?. Journal of Clinical Hypertension, 2018, 20, 1001-1007.	2.0	9
310	Extreme Dipping: Always Means Nocturnal Hypotension?. American Journal of Hypertension, 2019, 32, 842-847.	2.0	9
311	Left atrial volume in elite athletes: A metaâ€“analysis of echocardiographic studies. Scandinavian Journal of Medicine and Science in Sports, 2019, 29, 922-932.	2.9	9
312	Do reverse dippers have the highest risk of right ventricular remodeling?. Hypertension Research, 2020, 43, 213-219.	2.7	9
313	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. European Journal of Preventive Cardiology, 2022, 29, 1501-1509.	1.8	9
314	Reverse dipping and subclinical cardiac organ damage: a meta-analysis of echocardiographic studies. Journal of Hypertension, 2021, 39, 1505-1512.	0.5	9
315	Omega-3 Fatty Acids and Coronary Artery Disease: More Questions Than Answers. Journal of Clinical Medicine, 2021, 10, 2495.	2.4	9
316	Left Ventricular Hypertrophy and Sympathetic Activity. Advances in Experimental Medicine and Biology, 1997, 432, 173-179.	1.6	9
317	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 353-359.	2.2	9
318	Combination treatment in antihypertensive drug trials. , 1997, 11, 517-518.		8
319	Neuroadrenergic effects of calcium channel blockers. Journal of Hypertension, 2004, 22, 887-888.	0.5	8
320	Prevalence of cardiovascular risk factors in an unselected Italian population. Acta Cardiologica, 2009, 64, 771-778.	0.9	8
321	Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?. Journal of Hypertension, 2010, 28, 1809-1810.	0.5	8
322	Blood pressure control in resistant hypertension: new therapeutic options. Expert Review of Cardiovascular Therapy, 2010, 8, 1579-1585.	1.5	8
323	The central sympathetic nervous system in hypertension. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 329-335.	1.8	8
324	Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation. Current Vascular Pharmacology, 2014, 12, 63-68.	1.7	8

#	ARTICLE	IF	CITATIONS
325	Impact of different dipping patterns on left atrial function in hypertension. <i>Journal of Hypertension</i> , 2020, 38, 2245-2251.	0.5	8
326	Nocturnal blood pressure: the dark side of white-coat hypertension. <i>Journal of Hypertension</i> , 2020, 38, 2404-2408.	0.5	8
327	Clinical correlates and subclinical cardiac organ damage in different extreme dipping patterns. <i>Journal of Hypertension</i> , 2020, 38, 858-863.	0.5	8
328	Predictive Importance of Blood Pressure Characteristics With Increasing Age in Healthy Men and Women. <i>Hypertension</i> , 2021, 77, 1076-1085.	2.7	8
329	Phosducin "a candidate gene for stress-dependent hypertension. <i>Journal of Clinical Investigation</i> , 2009, 119, 3515-8.	8.2	8
330	Neuroadrenergic activation in obstructive sleep apnoea syndrome: a new selected meta-analysis - revisited. <i>Journal of Hypertension</i> , 2022, 40, 15-23.	0.5	8
331	Incident aortic root dilatation in the general population: findings from the Pamela study. <i>Journal of Hypertension</i> , 2022, 40, 544-552.	0.5	8
332	Sympathetic activation and heart rate thresholds for cardiovascular risk in chronic kidney disease. <i>Journal of Hypertension</i> , 2022, 40, 1530-1536.	0.5	8
333	Impact of new clinical trials on recent guidelines on hypertension management. <i>Annals of Medicine</i> , 2011, 43, 124-132.	3.8	7
334	Selective endothelin receptor blockade in resistant hypertension: results of the DORADO trial. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 153-155.	1.8	7
335	Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study. <i>Advances in Therapy</i> , 2016, 33, 2173-2187.	2.9	7
336	Baroreflex Activation Therapy in Congestive Heart Failure: Novel Findings and Future Insights. <i>Current Hypertension Reports</i> , 2016, 18, 60.	3.5	7
337	Monotherapy vs combination treatments of different complexity: a meta-analysis of blood pressure lowering randomized outcome trials. <i>Journal of Hypertension</i> , 2021, 39, 846-855.	0.5	7
338	Myocardial strain and left ventricular geometry: a meta-analysis of echocardiographic studies in systemic hypertension. <i>Journal of Hypertension</i> , 2021, 39, 2297-2306.	0.5	7
339	Clinical Relevance of the Sympathetic"Vascular Interactions in Health and Disease. <i>Biomedicines</i> , 2021, 9, 1007.	3.2	7
340	Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. <i>Blood Pressure</i> , 2006, 15, 268-274.	1.5	6
341	Management of very elderly hypertensives: the HYVET study. <i>Aging Clinical and Experimental Research</i> , 2008, 20, 494-495.	2.9	6
342	Multiple sampling improves norepinephrine reproducibility in essential hypertension: a comparison with the microneurographic technique. <i>Journal of Hypertension</i> , 2008, 26, 2185-2190.	0.5	6

#	ARTICLE	IF	CITATIONS
343	Antihypertensive treatment and stroke prevention: From recent meta-analyses to the PROfESS trial. <i>Current Hypertension Reports</i> , 2009, 11, 265-270.	3.5	6
344	Association Between Atrial, Ventricular and Vascular Morphofunctional Alterations in Rheumatoid Arthritis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 97-104.	2.2	6
345	Sympathetic and baroreflex abnormalities in the uncomplicated prediabetic state. <i>Journal of Hypertension</i> , 2018, 36, 1195-1200.	0.5	6
346	Does gender affect the association between right ventricular strain and arterial hypertension?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1327-1333.	2.0	6
347	Left ventricular hypertrophy in isolated and dual masked hypertension. <i>Journal of Clinical Hypertension</i> , 2020, 22, 673-677.	2.0	6
348	Neuroadrenergic activation in obstructive sleep apnea syndrome: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2021, 39, 2281-2289.	0.5	6
349	Regression of left ventricular hypertrophy in primary aldosteronism after adrenalectomy: a meta-analysis of echocardiographic studies. <i>Journal of Hypertension</i> , 2021, 39, 775-783.	0.5	6
350	Uric Acid, Hypertensive Phenotypes, and Organ Damage: Data from the Pamela Study. <i>Current Hypertension Reports</i> , 2022, 24, 29-35.	3.5	6
351	Endothelial Dysfunction: From a Pathophysiological Mechanism to a Potential Therapeutic Target. <i>Biomedicines</i> , 2022, 10, 78.	3.2	6
352	Secondary prevention of stroke: Old and new evidence. <i>Aging Clinical and Experimental Research</i> , 2002, 14, 216-220.	2.9	5
353	Cardiovascular and sympathetic effects of reversing insulin resistance in hypertension. <i>Journal of Hypertension</i> , 2004, 22, 1671-1672.	0.5	5
354	Hyperadrenergic and Labile Hypertension. , 2007, , 719-726.		5
355	The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2421-2424.	1.8	5
356	The morning blood pressure surge. <i>Journal of Hypertension</i> , 2011, 29, 2316-2319.	0.5	5
357	Targets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People. <i>Diabetes Care</i> , 2013, 36, S292-S300.	8.6	5
358	Long-term changes in left ventricular mass echocardiographic findings from a general population. <i>Journal of Hypertension</i> , 2017, 35, 2303-2309.	0.5	5
359	Carotid intima-media thickness and anti-hypertensive treatment: Focus on angiotensin II receptor blockers. <i>Pharmacological Research</i> , 2018, 129, 20-26.	7.1	5
360	â€œKeep an eyeâ€™ on the heart: retinal microcirculation disarray in congestive heart failure. <i>European Heart Journal</i> , 2018, 39, 57-59.	2.2	5

#	ARTICLE	IF	CITATIONS
361	Severe systemic cytomegalovirus infection in an immunocompetent patient outside the intensive care unit: a case report. <i>BMC Infectious Diseases</i> , 2019, 19, 34.	2.9	5
362	Does established vascular kidney disease exist?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 296-298.	2.0	5
363	Hypertension and Periodontitis: An Upcoming Joint Report by the Italian Society of Hypertension (SIIA) and the Italian Society of Periodontology and Implantology (SIdP). <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 1-3.	2.2	5
364	Blood pressure variability: a new therapeutic target on the horizon. <i>Journal of Hypertension</i> , 2021, 39, 1771-1773.	0.5	5
365	Blood Pressure Control and Antihypertensive Treatment. <i>Current Vascular Pharmacology</i> , 2012, 10, 506-511.	1.7	5
366	Home and ambulatory blood pressure in resistant hypertension. <i>EuroIntervention</i> , 2013, 9, R35-R41.	3.2	5
367	The PAMELA research project: a 25-year long journey. <i>Panminerva Medica</i> , 2021, 63, .	0.8	5
368	Elevated resting heart rate as independent in-hospital prognostic marker in COVID-19. <i>Cardiology Journal</i> , 2022, 29, 181-187.	1.2	5
369	Intermediate versus hard end points in clinical trials on hypertension. <i>Current Hypertension Reports</i> , 2005, 7, 294-297.	3.5	4
370	Implementation of new evidence into hypertension guidelines: the case of the ONTARGET and TRANSCEND trials. <i>Journal of Hypertension</i> , 2009, 27, S40-S44.	0.5	4
371	Indices of sympathetic activity and the paradox of chromogranin A. <i>Journal of Hypertension</i> , 2010, 28, 676-678.	0.5	4
372	Failure of monolateral renal nerve ablation to exert sympathoinhibitory and blood pressure lowering effects in a patient with resistant hypertension: A case report. <i>International Journal of Cardiology</i> , 2013, 169, e120-e121.	1.7	4
373	White Coat Hypertension. , 2015, , .		4
374	Threshold and Target for Blood Pressure Lowering in the Elderly. <i>Current Atherosclerosis Reports</i> , 2016, 18, 70.	4.8	4
375	Effects of serum uric acid on blood-pressure lowering treatment. <i>Current Medical Research and Opinion</i> , 2017, 33, 15-19.	1.9	4
376	Quarter Dose Combination Therapy. <i>Hypertension</i> , 2017, 70, 32-34.	2.7	4
377	Sympathomodulation in congestive heart failure: From drugs to devices. <i>International Journal of Cardiology</i> , 2020, 321, 118-125.	1.7	4
378	Impact of heart rate on arterial stiffness: virtual vs. real assessment. <i>Journal of Hypertension</i> , 2020, 38, 2382-2383.	0.5	4

#	ARTICLE	IF	CITATIONS
379	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. <i>European Heart Journal Supplements</i> , 2021, 23, B77-B81.	0.1	4
380	Left ventricular global longitudinal strain in secondary hypertension: A meta-analysis of echocardiographic studies. <i>European Journal of Internal Medicine</i> , 2022, 96, 81-89.	2.2	4
381	Relationships between sympathetic markers and heart rate thresholds for cardiovascular risk in chronic heart failure. <i>Clinical Research in Cardiology</i> , 2023, 112, 59-67.	3.3	4
382	The PAMELA (Pressioni Arteriose Monitorate E Loro Associazioni) Study. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 83-88.	2.2	3
383	Sympathoinhibitory effects of statins in chronic kidney disease. <i>Journal of Hypertension</i> , 2011, 29, 2064-2067.	0.5	3
384	A lesson from polycystic ovarian syndrome: untangling the role of renal sympathetic nervous system on hypertension and insulin resistance. <i>Journal of Hypertension</i> , 2011, 29, 836-837.	0.5	3
385	Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension. <i>Journal of Hypertension</i> , 2013, 31, 259-260.	0.5	3
386	Device-based treatments in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1502-1504.	0.5	3
387	The enigma of obesity-induced hypertension mechanisms in the youth. <i>Journal of Hypertension</i> , 2016, 34, 191-192.	0.5	3
388	Short-term blood pressure variability in acute coronary syndrome. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1249-1251.	2.0	3
389	Sympathomodulatory effects of sodium-glucose transporter-2 inhibitors in the kidneys and beyond. <i>Journal of Hypertension</i> , 2017, 35, 1966-1967.	0.5	3
390	Refractory hypertension focus on nighttime blood pressure and nondipping. <i>Journal of Clinical Hypertension</i> , 2018, 20, 447-449.	2.0	3
391	Big Data and Blood Pressure Control: Insights from the PAMELA and BP-CARE Study Cohorts. <i>Current Hypertension Reports</i> , 2018, 20, 82.	3.5	3
392	Right ventricular mechanics in patients with aortic stenosis and preserved ejection fraction: Is arterial hypertension a new player in the game?. <i>Journal of Clinical Hypertension</i> , 2019, 21, 516-523.	2.0	3
393	Masked Uncontrolled Hypertension. <i>Hypertension</i> , 2019, 73, 39-41.	2.7	3
394	The European Society of Cardiology (ESC)/European Society of Hypertension (ESH) 2018 guidelines for hypertension diagnosis and treatment: New concepts and recommendations. <i>Pharmacological Research</i> , 2019, 139, 489-490.	7.1	3
395	Big data, observational research and P-value: a recipe for false-positive findings? A study of simulated and real prospective cohorts. <i>International Journal of Epidemiology</i> , 2020, 49, 876-884.	1.9	3
396	Identifying poor cardiorespiratory fitness in overweight and obese children and adolescents by using heart rate variability analysis under resting conditions. <i>Blood Pressure</i> , 2020, 29, 13-20.	1.5	3

#	ARTICLE	IF	CITATIONS
397	Left ventricular mass and incident hypertension: Missing pieces in the puzzle. <i>Journal of Clinical Hypertension</i> , 2020, 22, 299-300.	2.0	3
398	Office and Out-of-Office Blood Pressure Changes Over a Quarter of Century. <i>Hypertension</i> , 2020, 76, 759-765.	2.7	3
399	Blood pressure variability correlates with right ventricular strain in women with gestational hypertension and preeclampsia. <i>Journal of Human Hypertension</i> , 2022, 36, 826-832.	2.2	3
400	Blood-pressure variability is associated with left-ventricular mechanics in patients with gestational hypertension and preeclampsia. <i>Hypertension Research</i> , 2021, 44, 1625-1632.	2.7	3
401	Sympatho-Vagal Imbalance in Hypertension. , 2012, , 345-348.		3
402	Limited reliability of heart rate as a sympathetic marker in chronic kidney disease. <i>Journal of Hypertension</i> , 2021, 39, 1429-1434.	0.5	3
403	Aging, physical fitness and endothelial function: are all ultracentenarians marathon runners?. <i>Clinical Science</i> , 2004, 106, 239-240.	4.3	2
404	Prevention of Microalbuminuria in Diabetes Mellitus: Results of the ROADMAP Trial. <i>Current Hypertension Reports</i> , 2011, 13, 265-267.	3.5	2
405	Differential patterns of regional neuroadrenergic cardiovascular drive in acromegalic disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 333-337.	1.9	2
406	Renal nerve ablation as a tool for studying the interactions between arterial stiffness, blood pressure and sympathetic drive. <i>Journal of Hypertension</i> , 2013, 31, 1782-1784.	0.5	2
407	Natriuretic peptides in the cross-talk of human cardiovascular and metabolic regulation. <i>Journal of Hypertension</i> , 2015, 33, 1139-1141.	0.5	2
408	Lercanidipine/enalapril combination in the management of obesity-related hypertension. <i>Integrated Blood Pressure Control</i> , 2016, 9, 69.	1.2	2
409	Response by Grassi et al to Letter Regarding Article, "The Sympathetic Nervous System Alterations in Human Hypertension". <i>Circulation Research</i> , 2016, 119, e35-6.	4.5	2
410	Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 289-296.	2.2	2
411	Albuminuria and diabetes. <i>Journal of Hypertension</i> , 2018, 36, 1036-1037.	0.5	2
412	The Sympathetic Nervous System in Hypertension. <i>Contemporary Endocrinology</i> , 2018, , 201-212.	0.1	2
413	How does blood pressure change in hypertensive patients with atrial fibrillation after successful electrical cardioversion?. <i>Journal of Clinical Hypertension</i> , 2019, 21, 369-371.	2.0	2
414	Is the association between sleep apnea and left ventricular hypertrophy obesity-independent?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1282-1283.	2.0	2

#	ARTICLE	IF	CITATIONS
415	Assessment of heart rate as a sympathetic biomarker™: strengths and pitfalls. <i>Journal of Hypertension</i> , 2020, 38, 1460-1461.	0.5	2
416	American Versus European Hypertension Guidelines: The Case of White Coat Hypertension. <i>American Journal of Hypertension</i> , 2020, 33, 629-633.	2.0	2
417	How to unmask masked hypertension: the role of office aortic blood pressure. <i>Hypertension Research</i> , 2021, 44, 256-258.	2.7	2
418	Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease. <i>Clinical Autonomic Research</i> , 2021, 31, 491-498.	2.5	2
419	A case of <i>Pseudomonas Aeruginosa</i> commercial tattoo infection. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 301-302.	0.2	2
420	Left ventricular mass reduction and hypertrophy regression following renal artery revascularization: a meta-analysis. <i>Journal of Hypertension</i> , 2021, 39, 4-11.	0.5	2
421	Targeting persistent normal left ventricular geometry in the general population: a 25-year follow-up study. <i>Journal of Hypertension</i> , 2021, 39, 952-960.	0.5	2
422	Sympathetic Drive as a Determinant of Weight Loss Intervention Outcome Strengths and Limitations. <i>American Journal of Hypertension</i> , 2005, 18, 1517-1518.	2.0	1
423	Blood pressure lowering effects of non-surgical procedures for vascular decompression: good news to be taken with caution. <i>Journal of Human Hypertension</i> , 2007, 21, 341-342.	2.2	1
424	Blood pressure control and therapeutic modulation of the adrenergic overdrive. <i>Current Hypertension Reports</i> , 2007, 9, 167-169.	3.5	1
425	The ACQUIRE trial. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1665-1667.	1.8	1
426	Evaluation of the ASPIRANT trial. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2573-2577.	1.8	1
427	Discovering the sympathomodulatory properties of new calcium channel blockers. <i>Journal of Hypertension</i> , 2014, 32, 1780-1781.	0.5	1
428	Obesity in childhood, ambulatory blood pressure and lifestyle interventions. <i>Journal of Hypertension</i> , 2014, 32, 1397-1399.	0.5	1
429	Dual renin-angiotensin system blockade and vascular remodeling. <i>Journal of Hypertension</i> , 2015, 33, 2392-2394.	0.5	1
430	Carotid Baroreceptor Stimulation in Resistant Hypertension and Heart Failure. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 233-239.	2.2	1
431	Role of Sympathetic Nervous System in the Metabolic Syndrome and Sleep Apnea. , 2015, , 165-175.		1
432	Response to Potential Errors and Omissions Related to the Analysis and Conclusions Reported in Cuspidi C, et al. <i>AJH</i> 2014; 27(2):146-156. <i>American Journal of Hypertension</i> , 2016, 29, 782-783.	2.0	1

#	ARTICLE	IF	CITATIONS
433	Prognostic significance of masked tachycardia in hypertension. Journal of Hypertension, 2017, 35, 468-470.	0.5	1
434	Glucose intolerance as the key risk factor for metabolic syndrome. Journal of Clinical Hypertension, 2017, 19, 848-849.	2.0	1
435	Baroreceptor Stimulation. , 2018, , 1323-1327.		1
436	The norepinephrine transporter deserves more attention. Journal of Hypertension, 2018, 36, 1472-1474.	0.5	1
437	Pheochromocytoma as a Clinical Model of Peripheral Sympathetic Overdrive: Old and New Findings. Current Hypertension Reports, 2019, 21, 90.	3.5	1
438	Extreme dipping: More complex than it looks. Journal of Clinical Hypertension, 2019, 21, 1284-1285.	2.0	1
439	Left ventricular mass and incident out-of-office hypertension in a general population. Journal of Hypertension, 2020, 38, 633-640.	0.5	1
440	Targeting White Coat Hypertension: Is the Daytime Enough?. American Journal of Hypertension, 2020, 33, 703-704.	2.0	1
441	The UrgeRe (Urgenze Ipertensive: Un Progetto Educazionale Fondato Sulla Vita Reale, Hypertensive) Tj ETQq1 1 0.784314 rgBT /Over 2021, 28, 151-157.	2.2	1
442	Hypertension and periodontitis: A joint report by the Italian society of hypertension (SIIA) and the Italian society of periodontology and implantology (SIdP). Oral Diseases, 2021, , .	3.0	1
443	Neurohormonal Interactions. , 2015, , 137-150.		1
444	Secondary Hypertension and Cardiovascular Risk: An Overview. Updates in Hypertension and Cardiovascular Protection, 2020, , 197-209.	0.1	1
445	Transient effects of carotid baroreflex stimulation via the neck chamber device on central venous pressure. Journal of Clinical Hypertension, 2021, , .	2.0	1
446	Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 137-144.	2.2	1
447	Assessment of 24-h neuroadrenergic profile: does the dream come true?. Journal of Hypertension, 2005, 23, 1137-1139.	0.5	0
448	Reviewer Critique of the Sympathetic Drive After Acute Myocardial Infarction in Hypertensive Patients. American Journal of Hypertension, 2006, 19, 1077-1078.	2.0	0
449	Response to Sympathetic Activity, Heart Failure, Obesity, and Metabolic Syndrome: Is There Any Role for Sleep Apnea?. Hypertension, 2007, 49, .	2.7	0
450	The Clinical Significance of Blood Pressure Lowering Treatment: Is First-Line Drug Choice Important?. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 117-119.	2.2	0

#	ARTICLE	IF	CITATIONS
451	Response to Possible Difference in the Sympathetic Activation on Extreme Dippers With or Without Exaggerated Morning Surge. <i>Hypertension</i> , 2009, 53, .	2.7	0
452	The TALENT Study. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 607-611.	1.8	0
453	The "Sympathetic" Kidney: Multiples Effects of Renal Sympathetic Nerve Ablation. <i>Current Hypertension Reviews</i> , 2012, 8, 250-255.	0.9	0
454	Sometimes you simply have to wait. <i>Journal of Hypertension</i> , 2012, 30, 1111-1113.	0.5	0
455	Insulin"endothelial interactions. <i>Journal of Hypertension</i> , 2012, 30, 673-675.	0.5	0
456	Neuroadrenergic abnormalities in hypertension and hypertension-related cardiovascular disease. <i>Hipertension Y Riesgo Vascular</i> , 2013, 30, 70-74.	0.6	0
457	European and British Guidelines on Hypertension. , 2013, , 433-440.		0
458	The "renaissance era"™ of sympathomodulatory interventions in the treatment of hypertension-related congestive heart failure. <i>Journal of Hypertension</i> , 2013, 31, 2133-2135.	0.5	0
459	"Broken"autonomic cardiac circadian clock in obese adolescents: evidence and implications. <i>Clinical Autonomic Research</i> , 2014, 24, 247-248.	2.5	0
460	Reply to the letter "Renal denervation: The potential causes of non-response" International Journal of Cardiology, 2014, 172, 624.	1.7	0
461	Does skin microcirculation represent a faithful mirror of uric acid alterations?. <i>Journal of Hypertension</i> , 2015, 33, 1531-1532.	0.5	0
462	Nondipping status and impaired nitroglycerin-mediated vasodilation in resistant hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1533-1535.	0.5	0
463	Microvascular function. <i>Journal of Hypertension</i> , 2015, 33, 928-930.	0.5	0
464	Evaluation of the SIGNIFY trial. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1861-1864.	1.8	0
465	Effects of Renal Denervation on Sympathetic Nervous System Activity. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016, , 303-319.	0.1	0
466	Precision medicine should become more "sympathetic"™ in managing hypertension. <i>Journal of Hypertension</i> , 2016, 34, 629-631.	0.5	0
467	Effects of renal denervation on short-term blood pressure variability. <i>Journal of Hypertension</i> , 2017, 35, 1780-1781.	0.5	0
468	Monographic issue of pharmacological research on hypertension. <i>Pharmacological Research</i> , 2018, 134, 221-222.	7.1	0

#	ARTICLE	IF	CITATIONS
469	Response to: Myocardial fibrosis and arrhythmogenesis in elite athletes. <i>Clinical Cardiology</i> , 2019, 42, 789-790.	1.8	0
470	Neural Mechanisms. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 71-86.	0.1	0
471	Response to: Gender differences and the association between right ventricular strain and arterial hypertension—A commentary. <i>Journal of Clinical Hypertension</i> , 2019, 21, 139-140.	2.0	0
472	Shades of grey: a matter relevant to sympathetic activity and blood pressure control?. <i>Journal of Hypertension</i> , 2020, 38, 206-207.	0.5	0
473	Impaired Autonomic Blood Pressure and Blood Volume Control in Chronic Renal Failure. , 2010, , 291-297.		0
474	Resistant Hypertension: Epidemiological and Evolving Therapeutic Concepts. , 2012, , 25-32.		0
475	The Role of Carotid Baroreceptor Stimulation. , 2013, , 137-144.		0
476	Neurogenic and Non-neurogenic Mechanisms of White-Coat Hypertension. , 2015, , 51-60.		0
477	Arterial Alterations in Hypertension. , 2015, , 285-297.		0
478	Neurogenic Hypertension. , 2018, , 381-382.		0
479	Treatment of Resistant Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , 639-652.	0.1	0
480	Nocturnal Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , 663-673.	0.1	0
481	The Role of the Brain in Neurogenic Prehypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 349-360.	0.1	0
482	Microvascular Alterations in Obesity. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020, , 137-147.	0.1	0
483	Introduction to the monographic issue "Recent ongoing epidemiological studies in Italy". <i>Panminerva Medica</i> , 2021, 63, .	0.8	0
484	Title is missing!. , 2020, 15, e0237297.		0
485	Title is missing!. , 2020, 15, e0237297.		0
486	Title is missing!. , 2020, 15, e0237297.		0

#	ARTICLE	IF	CITATIONS
487	Title is missing!., 2020, 15, e0237297.		0
488	Title is missing!., 2020, 15, e0237297.		0
489	Title is missing!., 2020, 15, e0237297.		0
490	Historical Archive of Blood Pressure and Evolution of Hypertension. Journal of Drug Delivery and Therapeutics, 2022, 12, 215-219.	0.5	0